Significant unmet need for regulated product in $2B US testing market Opportunity for expedited pathway for kitted product in development IRVINE, CA, December 06, 2023 – Oncocyte Corporation (NASDAQ:OCX), a precision diagnostics company, today announced it has begun the FDA single-site process for its VitaGraft transplant assays. The single-site process is a well-established pathway for … Continue reading Oncocyte Begins FDA Submissions Process for VitaGraft Transplant Assays